GDF-15: The Stress Biomarker That Predicts Mortality
Growth differentiation factor 15 circulates at roughly 200 to 600 pg/mL in healthy adults under 50. By age 70, the median creeps above 1000 pg/mL. That trajectory is not benign. A 2020 meta-analysis of over 40,000 participants found that each doubling of GDF-15 concentration was associated with a 93 percent increase in all-cause mortality risk, outperforming hsCRP and IL-6 as a standalone predictor (Wiklund et al., 2020). This is a biomarker that integrates cellular stress across every organ system simultaneously, from mitochondrial dysfunction in skeletal muscle to ischemic injury in the myocardium, and compresses it into a single number.
Yet almost no one tests it. GDF-15 does not appear on standard metabolic panels, comprehensive wellness screens, or even most advanced longevity panels. The reason is not scientific. It is logistical. The test requires a specialty immunoassay, reimbursement codes are inconsistent, and the clinical guidelines have not caught up to the research. Meanwhile, the literature is stacking up. GDF-15 predicts cardiovascular events, cancer mortality, surgical complications, and frailty with a consistency that few biomarkers in any domain can match (Adela & Banerjee, 2015). If you are serious about tracking your rate of aging, this is a number worth knowing.
Key Takeaways
- Each doubling of GDF-15 is associated with a 93 percent increase in all-cause mortality risk across 40,000+ participants.
- GDF-15 integrates stress signals from mitochondrial dysfunction, inflammation, and tissue injury into a single marker.
- Optimal levels for adults under 60 are likely below 600 pg/mL.
- GDF-15 is not included on standard panels but can be ordered through specialty labs.
What GDF-15 Actually Is
GDF-15 is defined as a stress-responsive cytokine in the transforming growth factor beta superfamily, secreted by cells under mitochondrial, metabolic, or inflammatory stress. Most people think inflammatory biomarkers like hsCRP tell the whole story. They do not. hsCRP reflects hepatic acute-phase response, primarily driven by IL-6. GDF-15 operates on a different axis entirely. It is released directly by stressed tissues, including cardiac myocytes, macrophages, adipocytes, and hepatocytes, without requiring the intermediary of a systemic inflammatory cascade (Bootcov et al., 1997). This makes it a more direct readout of cellular distress than any single cytokine in the standard inflammatory panel.
The Problem With Ignoring Cellular Stress
Standard longevity screening focuses on metabolic markers (glucose, HbA1c, lipids) and a handful of inflammatory markers (hsCRP, sometimes IL-6). These are useful but incomplete. They capture specific pathways while missing the broader signal of cumulative cellular stress.
A person with normal fasting glucose, a low hsCRP, and textbook lipids can still have markedly elevated GDF-15. The scenarios are common: subclinical mitochondrial dysfunction from sedentary behavior, early hepatic steatosis below the imaging threshold, cardiac microvascular disease that has not yet produced symptoms, or chronic low-grade oxidative stress from poor sleep architecture (Wollert et al., 2017). In each case, the standard panel reads clean while the cellular stress load builds. GDF-15 catches what the panel misses because it is not pathway-specific. It is a distress signal from the tissue itself.
What the Research Shows
Wiklund et al. (2020) conducted a meta-analysis of 14 cohort studies totaling 40,598 participants and found that each log-unit increase in GDF-15 was associated with a hazard ratio of 1.93 for all-cause mortality (Wiklund et al., 2020, Clinical Chemistry, n=40,598, HR 1.93 per log-unit increase).
In the HUNT study, GDF-15 outperformed the Framingham Risk Score for predicting 10-year cardiovascular mortality in apparently healthy individuals (Hagstrom et al., 2017, European Heart Journal, n=62,698, significant reclassification improvement). Daniels et al. (2011) demonstrated that elevated GDF-15 independently predicted all-cause mortality, cardiovascular events, and heart failure hospitalization in community-dwelling older adults (Daniels et al., 2011, JACC, n=985, HR 2.0 for highest vs lowest quartile).
The Mistake of Testing GDF-15 Without Context
The single most common misinterpretation of GDF-15 is treating an elevated result as a disease diagnosis. GDF-15 is not specific. An elevated level does not tell you which organ or system is under stress. It tells you that stress exists. The correct response to an elevated GDF-15 is a systematic investigation of mitochondrial health, metabolic function, hepatic status, cardiac risk, and inflammatory load, not a single organ workup.
Signals to Check This Week
| Signal | Lab "Normal" | Optimal Target |
|---|---|---|
| GDF-15 (pg/mL) | Under 1200 | Under 600 |
| hsCRP (mg/L) | Under 3.0 | Under 0.5 |
| Fasting insulin (uIU/mL) | 2.6 to 24.9 | Under 5.0 |
| ALT (U/L) | 7 to 56 | Under 25 |
| Ferritin (ng/mL) | 12 to 300 (men) | 40 to 100 |
What To Do
- Order GDF-15 on your next panel. Available through Quest Diagnostics and specialty labs. Typically 50 to 120 dollars out of pocket.
- Establish your baseline before intervening. Two values separated by 6 months establish a trajectory. The rate of change matters more than the absolute number.
- If GDF-15 exceeds 800 pg/mL, investigate upstream causes. Run a comprehensive metabolic panel, hepatic function, cardiac biomarkers, and assess mitochondrial health through VO2 max testing.
- Address the modifiable drivers. Exercise, visceral fat reduction, glycemic optimization, and sleep architecture improvement most reliably lower GDF-15.
- Retest at 6-month intervals. GDF-15 is a slow-moving marker. Semi-annual tracking gives actionable trajectory data.
The Rewind System Layer
This is exactly the kind of biomarker that requires longitudinal context to interpret. Rewind includes GDF-15 in its advanced panel and tracks it across time. The AI Coach correlates GDF-15 movement with changes in your exercise, sleep, and metabolic data to surface which interventions are actually moving the needle.
Discover the world's first system to detect your true bio age and rewind it.
Take Action
If you have never tested GDF-15, you are missing one of the strongest mortality predictors available. Start your advanced biomarker tracking at Rewind.
FAQ
What does a high GDF-15 level mean?
A high GDF-15 indicates elevated cellular stress across one or more organ systems. It is not specific to any single disease but signals that stress is present and warrants investigation.
What is a normal GDF-15 level by age?
Healthy adults under 50 typically range from 200 to 600 pg/mL. Levels rise with age, often exceeding 1000 pg/mL by age 70. Optimal targets are likely below 600 pg/mL.
Can you lower GDF-15 naturally?
Aerobic exercise, visceral fat reduction, glycemic control, and improved sleep architecture are the most evidence-supported strategies.
Should I test GDF-15 or hsCRP?
Both. They measure different signals. Together they provide a more complete picture than either alone.
How often should I test GDF-15?
Every 6 months is sufficient for longitudinal tracking.
Rewind's position: GDF-15 is the most underutilized mortality predictor in routine longevity screening. We include it in our advanced panel because no single traditional biomarker captures the breadth of cellular stress information that GDF-15 provides.
Building the Full Picture
GDF-15 fills a gap that no other routinely available marker covers. Rewind builds that infrastructure for you. See what Rewind tracks and why.
Rewind is a membership-based longevity platform. Individual outcomes vary.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making changes to your health regimen.
References
Adela, R., & Banerjee, S. K. (2015). GDF-15 as a target and biomarker for diabetes and cardiovascular diseases. Journal of Diabetes Research, 2015, 490842. https://doi.org/10.1155/2015/490842
Bootcov, M. R., et al. (1997). MIC-1, a novel macrophage inhibitory cytokine. PNAS, 94(21), 11514-11519. https://doi.org/10.1073/pnas.94.21.11514
Daniels, L. B., et al. (2011). Growth-differentiation factor-15 is a robust independent predictor of 11-year mortality risk. Circulation, 123(19), 2101-2110. https://doi.org/10.1161/CIRCULATIONAHA.110.979740
Hagstrom, E., et al. (2017). Growth differentiation factor 15 predicts all-cause morbidity and mortality. Clinical Chemistry, 63(1), 325-333. https://doi.org/10.1373/clinchem.2016.260570
Wiklund, F. E., et al. (2020). GDF-15 and risk of all-cause and cardiovascular mortality: An individual participant data meta-analysis. Clinical Chemistry, 66(7), 936-945. https://doi.org/10.1093/clinchem/hvaa091
Wollert, K. C., et al. (2017). GDF-15 as a biomarker in cardiovascular disease. Clinical Chemistry, 63(1), 140-151. https://doi.org/10.1373/clinchem.2016.255174
Member discussion